| Patent application number | Description | Published |
|---|
| 20090117171 | Compositions and methods for treatment of macular degeneration and related conditions - The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. The methods comprise administering a composition comprising a compound that is an antagonist of a G protein coupled receptor, e.g., the C5a receptor, to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization. The invention provides compositions comprising a compound that is an antagonist of a G protein coupled receptor linked either directly or indirectly to a moiety that binds to a component present on or at the surface of cell or noncellular molecular entity, e.g., a component present in the eye of a subject at risk of or suffering from age related macular degeneration or a related condition or choroidal neovascularization. | 05-07-2009 |
| 20090220572 | Injectable Combination Therapy for Eye Disorders - The present invention provides composition, methods, and articles of manufacture for treating an eye disorder, e.g., a disorder characterized by macular degeneration, choroidal neovascularization, or retinal neovascularization. One method of the invention comprises the step of: administering first and second therapeutic agents to the subject's eye in a single procedure, wherein the first therapeutic agent provides rapid improvement in the condition of the subject's eye and the second therapeutic agent is administered as a sustained release formulation of the second therapeutic agent. For example, the first and second therapeutic agents are administered by intravitreal injection. The first therapeutic agent may be dissolved in a liquid medium located in the syringe and the sustained formulation of the second therapeutic agent may comprise an ocular implant or plurality of particles located in the needle. The therapeutic agents may be selected from the group consisting of angiogenesis inhibitors and complement inhibitors. | 09-03-2009 |
| 20100166862 | Local Complement Inhibition for Treatment of Complement-Mediated Disorders - The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation of one or more locally produced complement proteins. The invention provides sustained release formulations and devices comprising a complement inhibitor and methods of use thereof. | 07-01-2010 |
| 20110092446 | COMPOSITIONS AND METHODS FOR TREATMENT OF TRAUMA - The present invention features the use of a complement inhibitor, e.g., a compstatin analog for treating an individual who has suffered a severe injury. In some embodiments, the complement inhibitor may be administered within 24 hours following the injury and optionally also at later time points. The complement inhibitor may, for example, be administered prior to transporting the patient to a health care facility, during transport of the patient to a health care facility, or in the emergency department. Further provided are methods of selecting individuals for such therapy. Further provided are methods of identifying individuals at increased risk of poor outcome following trauma. In certain embodiments the methods comprise determining whether the genotype of the patient includes an allele of a polymorphism in or near a complement-related gene, wherein said allele is associated with risk of poor outcome following trauma. | 04-21-2011 |
| 20110182877 | SUSTAINED DELIVERY OF COMPSTATIN ANALOGS FROM GELS - The present invention features the sustained delivery of compstatin analog and, optionally, an additional active agent, by release from a macroscopic, gel-like deposit formed by administering a liquid solution containing the compstatin analog to an extravascular location in the body of a mammalian subject such as the vitreous chamber. | 07-28-2011 |
| 20110190221 | MODULATION AND REPLETION/ENHANCEMENT OF THE COMPLEMENT SYSTEM FOR TREATMENT OF TRAUMA - The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods for repleting and/or enhancing complement activation capacity in a subject who has suffered a traumatic injury. | 08-04-2011 |
| Patent application number | Description | Published |
|---|
| 20100190424 | Reinforced Bonded Abrasive Tools - Bonded abrasive tools, e.g., grinding wheels, can be reinforced using, for instance, one or more fibreglass web(s) having a surface of glass per unit of at least 0.2. Alternatively or in addition, the fibreglass web has a thickness of 2 mm or less. The web can be designed to provide improved adhesion between the fibreglass reinforcement and the mixture employed to form the bonded abrasive tool. In some examples, the middle reinforcement at the neutral zone of the wheel can be eliminated or minimized. | 07-29-2010 |
| 20110027564 | ABRASIVE TOOL HAVING CONTROLLED POROSITY DISTRIBUTION - An abrasive tool having a body including an abrasive portion having abrasive grains contained within a matrix material and porosity characterized by a bimodal distribution of pores including large pores having an average large pore size (P | 02-03-2011 |
| 20110041413 | ABRASIVE TOOL HAVING A PARTICULAR POROSITY VARIATION - An abrasive tool has a body including an abrasive portion having abrasive grains contained within a matrix material, and a first reinforcing member contained within the abrasive portion, wherein the body comprises a porosity variation difference through at least half of a thickness of the body of not greater than 250% from a mean porosity of the body. | 02-24-2011 |
